These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29278968)

  • 1. Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting.
    Di Lorenzo R; Cameli M; Piemonte C; Bolondi M; Landi G; Pollutri G; Spattini L; Moretti V; Ferri P
    Nord J Psychiatry; 2018 Apr; 72(3):214-220. PubMed ID: 29278968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.
    Sağlam Aykut D
    J Clin Psychopharmacol; 2019; 39(1):57-62. PubMed ID: 30566417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.
    Levitan B; Markowitz M; Turkoz I; Fu DJ; Gopal S; Alphs L
    Int Clin Psychopharmacol; 2016 Nov; 31(6):315-22. PubMed ID: 27434314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).
    Parellada E; Bioque M; Serrano M; Herrera B; García Dorado M;
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):191-199. PubMed ID: 29161951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
    Pesa JA; Doshi D; Wang L; Yuce H; Baser O
    Curr Med Res Opin; 2017 Apr; 33(4):723-731. PubMed ID: 28044455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.
    Hargarter L; Lahaye M; Cherubin P; Lambert M; Swarz M; Joldygulov G; Vischia F; Chomskaya V; Bozikas VP; Tsapakis EM; Schreiner A
    World J Biol Psychiatry; 2018; 19(sup3):S147-S157. PubMed ID: 28594264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies.
    Emsley R; Parellada E; Bioque M; Herrera B; Hernando T; García-Dorado M
    Int Clin Psychopharmacol; 2018 Jan; 33(1):15-33. PubMed ID: 28817397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making.
    Pappa S; Barnett J; Mason K
    CNS Drugs; 2023 Jan; 37(1):107-116. PubMed ID: 36495380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.